High-throughput Genotyping

NGS-based target enrichment methods for higher genotyping efficiency in plant and animal research

Overview

For Molecular Breeding, the Availability and Easy Accessibility of Genomic Resources is a Prerequisite

Although technological advances have provided a range of resources like molecular markers, genetic linkage maps, whole genome sequences, and transcriptomes, agricultural genomics has been facing many challenges.


Celemics provides the solution with our high-throughput genotyping panel.


We have utilized NGS and hybridization-based capture technology, whereby a high number of regions of interest are simultaneously enriched using specifically designed probe, to provide new insights into different agricultural genomics research.

High-Throughput Genotyping Panel
Features & Benefits

NGS-based Target Enrichment
Sequencing Assay

Utilizing NGS-based target enrichment method for higher accuracy and cost-effective experiment compared to conventional methods such as conventional GBS, PCR, and microarray

Comprehensive Analysis with High Accuracy

Perform comprehensive assay of 100 to 10,000 markers with minimized false-negative and false-positives as well as for discovering novel SNPs

Outstanding Performance Regardless of Various Origins

Receive high-quality results enabled by species-specifically designed blocking oligos across all types of origins

Maximized Analytic Efficiency

Benefit from Celemics’ library preparation kits, target capture technology, and multiplexing indices specifically designed for high-throughput genotyping

Comparison with Conventional Technologies

Advantages Disadvantage
Conventional GBS 1. Sequencing of multiple samples due to lower amount of data required compared to WGS 1. Limited biomarkers available due to limited conserved regions, reducing overall resolution
2. Unable to detect SNPs in the restriction sites
Microarray
1. Higher reproducibility than conventional
GBS
1. Hard to customize new targets (novel biomarkers)
2. Low flexibility to meet various kinds of genotyping
PCR 1. Cost-effective for low number of samples 2. Easy and fast analysis 1. Limited number of biomarkers to analyze at once
2. Inappropriate for mass-analysis of biomarkers
Celemics Target Enrichment 1. Cost saving : Highly cost-effective when assessing multiple samples
2. Flexible customization : Novel biomarkers can be added or removed
3. Comprehensive analysis : Including novel SNP discovery
4. Exceptional performance : Celemics proprietary blocking oligo design technology
5. Wide compatibility : Compatible with a wide range of sample types

Related Products

Customized NGS Panel

Customization to Next Level; tailored NGS panel customization and assay optimization

related-product

Highly optimized, user- convenient NGS library preparation kit for all Celemics panels

Celemics Analysis Service

End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis

Streptavidin Bead

Incomparable quality magnetic bead for simple, flexible, and reproducible purification

References

Epigenomics

Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel

Bae JM, Ahn JY, Lee H, Jang H, Han H, Jeong J, et al. Identification of tissue of origin in cancer of unknown primary using a targeted bisulfite sequencing panel. Epigenomics. 2022 May;14(10):615–28.

 

10.2217/epi-2021-0477


View Detail >

Investig Clin Urol

Germline pathogenic variants in unselected Korean men with prostate cancer

So MK, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022 May;63(3):294–300.

 

DOI 10.4111/icu.20220044


View Detail >

Scientific Reports

Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers

Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, et al. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers. Sci Rep. 2022 Feb 3;12(1):1842.

 

DOI 10.1038/s41598-022-05931-3


View Detail >

BMC Medical Genomics

A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report

Shin WY, Yoon SY, Park R, Kim JA, Song HH, Bang HI, et al. A novel bi-alleleic DDX41 mutations in B-cell lymphoblastic leukemia: case report. BMC Med Genomics. 2022 Mar 4;15(1):46.

 

DOI 10.1186/s12920-022-01191-2


View Detail >